Reviewing InfuSystem (NYSE:INFU) and Motus GI (NASDAQ:MOTS)

Motus GI (NASDAQ:MOTS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Insider and Institutional Ownership

20.1% of Motus GI shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 0.3% of Motus GI shares are held by company insiders. Comparatively, 11.4% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Motus GI has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Profitability

This table compares Motus GI and InfuSystem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	N/A	N/A	N/A
InfuSystem	1.12%	2.78%	1.41%

Analyst Ratings

This is a breakdown of current ratings for Motus GI and InfuSystem, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Motus GI	0	0	0	0	0.00
InfuSystem	0	1	2	2	3.20

InfuSystem has a consensus price target of $14.50, indicating a potential upside of 42.72%. Given InfuSystem’s stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Motus GI.

Valuation & Earnings

This table compares Motus GI and InfuSystem”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$319,000.00	0.00	-$12.87 million	($14.69)	0.00
InfuSystem	$141.05 million	1.46	$870,000.00	$0.26	39.08

InfuSystem has higher revenue and earnings than Motus GI. Motus GI is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Summary

InfuSystem beats Motus GI on 15 of the 15 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.